For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:

https://www.mycme.com/learn/course/recent-research-into-biologics-in-asthma-10830

Program Description

This podcast activity provides an in-depth review of several recent trials in severe asthma management, highlighting the ongoing shift in asthma precision medicine towards identifying the right patients for the right treatments. Clinicians will examine clinical data from the NIMBLE trial (depemokimab), alongside the WAYFINDER trial (tezepelumab), as well ZEPHYR 5 (benralizumab), REMOMEPO (mepolizumab), VESTIGE (dupilumab) and VALLIANT (verekitug). This activity will grant clinicians critical insights to move beyond simple exacerbation reduction and precisely align advanced biologic therapies with the underlying cellular biology driving each patient's symptoms.

Educational Objective

At the conclusion of this activity, participants should be better able to:

Review recent updates in the asthma literature, including recent guideline revisions and evolving clinical trial data for newer biologic therapies.

Accredited Providers

The National Association for Continuing Education in partnership with the Association for Pulmonary Advanced Practice Providers (APAPP).

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 

Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).

Faculty

Cedric Rutland, BS, MD, FCCP
Volunteer Faculty
University of California
Pulmonary Critical Care Internal Medicine, Producer
Rutland Medical Group
Newport Critical Care Physicians
Lake Forest, CA

Dr. Rutland has disclosed the following financial relationships:
Consultant: Sanofi (asthma, diabetes, NP, RSV, AD), Boehringer Ingelheim (IPF, PPF), Regeneron (asthma, diabetes, NP, RSV, AD), Chiesi (asthma), Baxter (bronchiectasis), Insmed (bronchiectasis), AstraZeneca (asthma, cough)
Advisor/Advisory Board: Sanofi (asthma, AD, NP), Regeneron (asthma, AD), Chiesi (asthma), Boehringer Ingelheim (IPF, PPF), AstraZeneca (asthma, cough)
Speaker: Sanofi (asthma, NP, AD, AFRS, urticaria, EoE), Regeneron (asthma, NP, AD, AFRS, urticaria, EoE), Boehringer Ingelheim (IPF, PPF), AstraZeneca (asthma, cough), Chiesi (asthma), Baxter (bronchiectasis)

These relationships have ended within last 24 months:
Consultant: GSK (asthma, cough, RSV)
Advisor/Advisory Board: GSK (asthma, cough, RSV)
Speaker: GSK (asthma, cough, RSV)

Diego J. Maselli, MD, FCCP, ATSF
Professor and Chief
Division of Pulmonary Diseases & Critical Care
UT Health at San Antonio
Director, Respiratory Care, University Health System
Director, Severe Asthma Program, University Health System
San Antonio, TX

Dr. Maselli has disclosed the following financial relationships:
Consultant: AstraZeneca (asthma, COPD), Sanofi/Regeneron (asthma, COPD), GSK ( asthma, COPD), Amgen (asthma, COPD), Insmed (bronchiectasis)
Speaker: GSK (asthma, COPD), AstraZeneca (asthma, COPD), Amgen (asthma, COPD), Sanofi/Regeneron (asthma, COPD)

All of the relevant financial relationships listed for these individuals have been mitigated.

Nurse Planner and Peer Reviewer

Marjorie Crabtree, DNP, FNP, ANP
Haymarket Medical Education
Steering Committee
Nurse Practitioner Healthcare Foundation
Accredited Provider Program Director
Bellevue, WA

Dr. Crabtree has no relevant conflicts of interest with any ACCME-defined ineligible company.

Accredited Provider Disclosure

NACE staff has no relevant financial relationships to disclose.

Intended Audience

Pulmonology, allergy/immunology, and critical care clinicians (physicians, nurse practitioners, and physician associates), as well as primary care and geriatric medicine clinicians caring for patients with asthma.

Commercial Supporters

This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.